Connect with us

Medical Research

InMed Finds Cannabinol (CBN) Cannabinoid May Benefit a Rare Skin Condition and Glaucoma

Pouline Ireri

Published

on

InMed Finds Cannabinol (CBN) Cannabinoid May Benefit a Rare Skin Condition and Glaucoma
- Ad -

A Biopharmaceutical company specializing in cannabinoid-based therapeutics, InMed Pharmaceuticals found that a lower concentrated cannabinol (CBN) within their formulas were effective in treatments involving skin conditions and eye-related disease reports Mugglehead.

InMed first got the approval to commence clinical trials of INM-755 in December 2019 after the regulatory and ethics committee gave their approval. Today, the INM-755 formula is deemed effective in treating epidermolysis bullosa, which is a rare type of skin condition. Similarly, the INM-088 formula garnered their attention, as it was effective in treating glaucoma.

Speaking in regard to the achievement attained is the CEO of InMed, Eric Adams who shared that over 30 preclinical pharmacology and toxicology studies have been conducted by the firm, who’ve reasoned that CBN’s therapeutic benefits shouldn’t be taken so lightly. In particular, he said:

“We are proud to be the first company to investigate cannabinol’s therapeutic potential in human clinical trials […] Identifying potential therapeutic advantages of CBN in specific disease models over […] THC and CBD.”

He also disclosed that moving forward, more biosynthetic manufacturing methods would be considered and therapeutic uses of CBN would be analyzed to address other health conditions.

Pouline Ireri lives in Kenya and is new at TOC but plans to contribute much more in the near future. She graduated from the University of Nairobi and is a Business consultant/Micro Finance specialist. Her affinity for cannabis and CBD came naturally through her own use and become an advocate based on the positive effects and results she experienced.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com